Next 10 |
home / stock / ctx:cc / ctx:cc news
Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the first quarter ended March 31, 2024 (“Q1-20...
Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the fourth quarter and fiscal year ended December 31,...
Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the third quarter ended September 30, 202...
Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“ Crescita ” or the “ Company ”) announced today that the Toronto Stock Exchange (the “ TSX ”) has approved the Company’s proposed normal course issuer bid (“ NCIB ȁ...
Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the second quarter ended June 30, 2023 (&...
Croma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe Canada NewsWire VIENNA , June 1, 2023 /CNW/ -- Croma-Pharma, a global player and challenger in the dynamically growing, minimally invasive aesthetics market, announces that it will launch Pliagl...
Strong Performance in Commercial Skincare Cash Balance of $10.3M Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driven Canadian commercial dermatology company,...
Record Annual Revenue of $23.5M, Up 40% Over F2021 F2022 Adjusted EBITDA 1 of $2.2M, Up 138% Over F2021 Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driv...
Sales Doubled with New Manufacturing Revenue Record of $4.3M Adjusted EBITDA 1 of $0.5M, up $1.0M Year-over-Year Cash Balance of $10.7M Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a gr...
Over 120% sales growth with Record Manufacturing Revenue of $3.9M Adjusted EBITDA 1 of $0.6M, up $0.9M Year-over-Year Repayment of $1.0 M of Convertible Debentures Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the ...
News, Short Squeeze, Breakout and More Instantly...
Crescita Therapeutics Inc. Company Name:
CTX:CC Stock Symbol:
TSXC Market:
Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the first quarter ended March 31, 2024 (“Q1-20...
Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the fourth quarter and fiscal year ended December 31,...
Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the third quarter ended September 30, 202...